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Case Presentation

A 33 year-old African American male with a past medical
history significant for HIV on HAART therapy presented
to the emergency department (ED) with acute onset of right
upper quadrant abdominal pain and mild shortness of breath.
The abdominal pain was not associated with any fevers, chills,
nausea, vomiting or diarrhea. The patient denied any chest
pain, palpitations, lightheadedness or syncopal episodes. He
did report some dysphagia with solids more than liquids over
the last 2 months as well as decreased oral intake. His review of
systems was otherwise significant for weight loss which he was
unable to quantify.
He denied any medication allergies. His medications on admission
included trimethoprim/sulfmethaxazole, azithromycin,
fluconazole, lopinavir/ritonavir, and emtricitabine/ tenofovir.
His most recent CD4 count was 114 cells/mm3 and he had no
other known past medical history.
On initial physical exam, the patient was found to be tachycardic
at 115 bpm, hypotensive with a blood pressure of 80/40 mm
Hg, and tachypneic exhibiting 32 resps/min. The head and
neck exam were significant for oral thrush. Other than resting
tachycardia, the cardiovascular exam was unremarkable. The
pulmonary exam was notable for tachypnea, but the lungs
were clear to auscultation and there was no observed accessory
muscle use. The abdominal exam was significant for tenderness
to palpation in the right upper quadrant without rebound or
guarding. The patient was alert and oriented and had no focal
neurological deficits.
Admission labs were notable for a white blood cell count of
19.3 cells/μL with 22% bands, creatinine 1.8 mg/dL (no baseline
available), total bilirubin 1.8 mg/dL, direct bilirubin 1.2 mg/dL
with an alkaline phosphatase of 1233 IU/L. AST and ALT were
90 U/L and 64 U/L, respectively. The patient was also noted to
have a lactate of 86.7 mEq/L.

Hospital Course

The patient responded to 3L normal saline fluid resuscitation
to 110/60 mm Hg. Broad spectrum antibiotics (vancomycin
and pipercillin/tazobactam) were begun and the patient was
admitted to a telemetry floor. Initial studies included an
abdominal ultrasound which showed 2 hypoechoic masses in
the left lobe of the liver without intra- or extrahepatic ductal
dilatation noted. A non-contrast CT of the abdomen and pelvis
demonstrated innumerable lymph nodes scattered diffusely
throughout the mesentery and retroperitoneum measuring up
to 1.5 cm, likely related to the history of HIV infection. A renal
ultrasound showed normal sized kidneys, and no hydronephrosis. The nephrology service was consulted and the working
diagnosis at the time was renal failure secondary to tenofivir.

The tenofivir was discontinued and his abdominal pain workup
was continued.
The hospital course was notable for diarrhea, progressive lethargy,
fevers up to 104° F, worsening abdominal pain, continued rise
in serum creatinine to 5.1 mg/dL, and decreased urine output
to 200 cc’s over 24 hours. On hospital day 3, the patient was
transferred to the intensive care unit after an arterial blood gas
demonstrated a profound metabolic acidosis characterized by
a pH 7.15. A repeat non- contrast CT of abdomen and pelvis
now revealed diffuse, marked small bowel and large bowel wall
thickening with two focal segments suggestive of small bowel
intussusceptions without bowel obstruction.
The patient’s abnormal though non-specific intra-abdominal
findings in the setting of worsening acidosis and elevated
lactate levels prompted an exploratory laparotomy. Seven areas
of easily reducible intussusceptions were discovered. In fact,
innumerable mesenteric lymph nodes were found, believed to
act as lead points for the pathogenesis of these intussusceptions.
Fortunately, the bowel was still viable avoiding the need for
resection.
Post-op, the patient continued to be oliguric with severe
electrolyte imbalances (Urate 27.5, K 6.2 mEq/L, Ca2+ 3.0 mEq/
L, PO43- 17.4 mEq/L, LDH 1154 mEq/L). Spontaneous tumor
lysis syndrome was diagnosed and the patient was begun on
emergent hemodialysis. Intra-operatively obtained mesenteric
lymph nodes demonstrated atypical lymphoid cells with a high
mitotic rate that focally demonstrate a “starry-sky” pattern
consistent with a diagnosis of Burkitt lymphoma. Due to the
patient’s poor functional & physiologic status, it was decided
that he was a poor candidate for chemotherapy. The patient
elected no other therapies and elected for hospice care.

Discussion

Burkitt lymphoma is a rare disorder comprising less than 1% of
non Hodgkin B cell lymphomas. First described by Dr. Dennis
Burkitt in Uganda in 1958, it is an aggressive lymphoma frequently
presenting in extranodal sites, or as a leukemia, characterized by
monomorphic medium sized cells with a basophilic cytoplasm
and very high proliferation rate. It is classified by three major
types: endemic, sporadic, and immunodeficient.1,2
The endemic form is most common in Africa and New Guinea,
where is it the most common childhood neoplasm. The endemic
form typically affects facial bones in children (mean age 4-7)
and is associated with EBV more than 95% of the time. The
sporadic form occurs most commonly in developed countries
and a mean age of onset of 30. The sporadic form arises from
lymphoid tissue in the gut and respiratory tract with most cases
being extranodal and jaw involvement less than 30% of the time.
The immunodeficient form is associated with HIV infection and
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most commonly affects the lymph nodes and bone marrow.
Paradoxically, these patients typically have a high CD4 count
with few opportunistic infections.
The clinical presentation is varied and nonspecific, but
frequently involves the abdomen (i.e. pain, ascites). Patients
may also present with classic B symptoms of fevers, night
sweats, and weight loss. The diagnosis is confirmed with lymph
node biopsy, bone marrow biopsy, and lumbar puncture (the
last two necessary for deciding on treatment options).
The biology of the disease involved chromosomal translocation
and dysregulation of the c-myc gene, which controls cellular
proliferation.1 Tumor cells express a high level of the ki 67 protein
indicating high levels of mitotic activity. On pathology, sheets of
B cells are seen with frequent mitotic figures classically giving
the tumor cells a “starry sky” appearance. It is important to
differentiate between Burkitt and diffuse large B cell lymphoma
(which can sometimes have a similar pathologic appearance)
because the former is a more aggressive type of lymphoma
requiring intrathecal chemotherapy. Recently, molecular gene
signatures have been used to aid in this differentiation.
Typically, the Ann Arbor system is used in staging lymphomas;
however, Burkitt lymphoma does not lend itself well to the
staging system due to its extremely aggressive course. Due to the
nature of the tumor, chemotherapy needs to be initiated as soon
as possible, preferably within 48 hours of diagnosis. A standard
regimen includes cyclophosphamide, vincristine, doxorubicin,

50

and high dose methotrexate and intrathecal therapy with
alternating ifosfamide, etoposide, and high dose cytarabine.
In one study, this regimen showed a 92% two year event free
survival in children and adults.3 The significant side effects
experienced were neurotoxicity, bone marrow suppression,
severe mucositis, and tumor lysis syndrome. Another study
showed that rituximab, a CD20 monoclonal antibody, further
increased two year event free survival (80-88%) when added to
the standard regimen. Studies are now under way with other
monoclonal antibodies and other biologic agents. There is no
clear role for bone marrow transplantation in the treatment of
the disease.
Once entertained, the diagnosis of Burkitt lymphoma should be
promptly confirmed with prompt initiation of chemotherapy to
combat the aggressive nature of this specific type of lymphoma.
New monocloncal antibody agents currently offer new survival
benefits not previously seen before.
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